Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease

This article was originally published here

The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetic profile of GFB-887 in healthy volunteers and in patients with chronic kidney disease. Topline safety data from

The post Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply